Harte Hanks, Inc. (HHS) Fair Value 2026 — DCF & Multi-Method Analysis | EvidInvest | EvidInvest

HHS — Fair Value Analysis

Harte Hanks, Inc.

Current: $3.99Overvalued

Fair Value Range

Bear Case (25th pct.)

$-23.88

-698.5% vs price

Base Case (Median)

$-14.35

-459.6% vs price

Bull Case (75th pct.)

$-4.83

-221.1% vs price

$-23.88$-14.35$-4.83

◇ = Current price | |Bear |Base | Bull

Method Breakdown

Method	Est. Value	vs Price	Weight
DCF (Discounted Cash Flow)	$-33.40	-937.0%	High (40%)
EV/EBITDA	$4.69	17.4%	Medium (20%)

Interpretation

Based on 2 out of 8 methods, HHS appears overvalued at the current price of $3.99. The base case fair value of $-14.35 implies 459.6% downside.

Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.